Atara Biotherapeutics, Inc.

As of June 30, 2026, Atara Biotherapeutics Inc carries a market capitalization of 94.43M, placing it among publicly traded companies globally. Its enterprise value stands at 94.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Atara Biotherapeutics Inc's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Atara Biotherapeutics Inc has 9.44M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 23.06, and the price-to-book ratio stands at -2.92.

These figures are as of June 30, 2026. The EV/Sales ratio of 17.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 94.44M versus a market cap of 94.43M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Atara Biotherapeutics Inc maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -26.70, indicating conservative leverage, while an interest coverage ratio of -4.99 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -57.62, reflecting losses generated across the asset base. The company generates approximately 111,212.48 in revenue per employee across its workforce of 48.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Atara Biotherapeutics Inc recorded 25,383.70 in income tax expense. The company reported a pretax loss of -14.58M and -14.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Atara Biotherapeutics Inc's stock has gained approximately 10.37% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Atara Biotherapeutics Inc generated 5.42M in revenue and converted that into -14.61M in net income, yielding earnings per share of -1.17. EBITDA reached -12.34M, while operating income came in at -12.45M.

As of June 30, 2026, Atara Biotherapeutics Inc holds 8.64M in cash and equivalents against 8.65M in total debt, resulting in a net debt position of -2.82M. Total book value stands at -32.38M, with working capital of 5.85M providing operational flexibility.

Atara Biotherapeutics Inc produced -19.16M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -19.16M - equivalent to -1.53 per share.

Over the twelve months ended June 30, 2026, Atara Biotherapeutics Inc posted a gross margin of 91.38, reflecting its pricing power and cost economics. The operating margin of -229.67 and net profit margin of -269.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.18, meaning Atara Biotherapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Atara Biotherapeutics Inc's most recent stock split took place on June 20, 2024 with a 25:1 split ratio.

As of June 30, 2026, Atara Biotherapeutics Inc has an Altman Z-Score of -135.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.